Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~FOR SCREENING~* Patients must have a histopathologic diagnosis of GBM.~* Patients from 5 to 65 years of age with GBM.~FOR TREATMENT~* GBM has progressed following primary therapy.~* Tumor is CMV pp65 or IE1 positive by immunohistochemistry (IHC).~* Subjects must have pulse oximetry \> or = 94 % on no supplemental oxygen.~* Creatinine clearance must be \> 50 cc/min as estimated by patient's serum creatinine, weight, and age.~* Bilirubin must be \< 2.0 mg/dl and SGOT/SGPT \< 2.5 X normal.~* ECOG performance status must be \< or = 2, and for patients \<16 years of age, Lansky performance status must be \> or = 70%.~Exclusion Criteria:~* Pregnant females~* Subjects who are moribund or who because of cardiac, pulmonary, renal, hepatic or neurologic dysfunction are not expected to survive one month following the T cell infusion

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GBM Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).